Mdxhealth, Sa

Johns Hopkins University

Oncomethylome Sciences, S.a.

Universiteit Gent

Mdxhealth

Wim Van Criekinge

Stephen B Baylin

Geert Trooskens

Josef Straub

Leslie Cope

James Herman

G Bea A Wisman

Ate G J Van Der Zee

E M D Schuuring

Isabelle Renard

Valerie Deregowski

Luc Dehaspe

James Clark

Johan Vandersmissen

Nathalie Sieben

Leander Van Neste

Marusya Lieveld

Davy Vanden Broeck

Kornel Schuebel

Ate G Van Der Zee

E M Schuuring

G Bea Wisman

Leander Vanneste

Emd Schuuring

Valérie Deregowski

Disclosed are methods for determining one or more nucleotides at one or more nucleotide positions of a polynucleotide sample, the polynucleotide sample comprising heterogeneous polynucleotides having different nucleotides at the nucleotide positions. The disclosed methods may be utilized to control for sequencing bias during sequencing of the polynucleotide sample. Suitable samples may include patient samples for use in diagnosing, prognosing, and treating the patient.

Methods and kits for identifying and adjusting for bias in sequencing of polynucleotide samples

Disclosed are methods for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells, including bladder cells present in a urine sample. Also disclosed are kits for performing the disclosed methods, such as kits for determining the methylation status of the promoter region of the TWIST1 gene comprising at least one primer pair for determining the methylation status of TWIST1. The kits may contain means for processing a urine sample.

Method for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells

The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof.

Methylation of the EPB41L3 gene or the promoter of the EPB41L3 gene in a test sample comprising cervical cells

Disclosed are methods for assessing the methylation and mutation status of nucleic acid in a sample. The methods provide for methylation-dependent modification of the nucleic acid in a sample, and subsequently nucleic acid amplification processes to distinguish between mutated and non-mutated target sequence.

Methods of detecting mutations in BRAF and epigenetic changes

Detection and prognosis of cervical cancer

Disclosed are methods of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprising detecting an epigenetic change, such as methylation, in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2, or a panel thereof. Also disclosed are kits for performing the disclosed methods, such as kits for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprising at least one primer pair for determining the methylation status of each of NID2, TWIST1 and RUNX3. The kits may contain means for processing a urine sample.

Methods for determining methylation of the TWIST1 gene for bladder cancer detection

Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting 'personalized medicine' treatments.

Methylation markers for diagnosis and treatment of ovarian cancer

Growing community of inventors

Waarloos, Belgium

Wim Van Criekinge